Navigation Links
Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
Date:10/20/2011

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss third quarter 2011 financial results, as well as provide a general business overview on Wednesday, November 2, 2011, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).  Financial results for the third quarter ended September 30, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at:
http://www.onyx-pharm.com/investors/event-calendar

or by dialing 847-585-4422 and using the passcode 9667816#.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 9667816# approximately one hour after the teleconference concludes.  The replay will be available through November 16, 2011. 

About Onyx Pharmaceuticals, Inc.

Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.  The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Investor-Edge has initiated coverage on ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ... Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,419.48, up 2.40%, the Dow Jones ...
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... , PALM CITY, Fla., Dec, 17 Connectyx Technologies ... it has formed a distribution partnership with United States ... Supplies, Respiratory Supplies and Medications as well as Bladder ... Terms of the partnership were not disclosed, however Connectyx ...
... 17 Instacare Corp. (OTC Bulletin Board: ISCR) a ... and diagnostics and at home testing products for the ... e-health technologies and revolutionary cell phone centric technologies and ... of its Fiscal 2010 guidance, the Board has determined ...
Cached Medicine Technology:Connectyx Announces Distribution Partnership with United States Medical Supply 2Connectyx Announces Distribution Partnership with United States Medical Supply 3Instacare Corp. Board of Directors Sets Growth Plans for 2010 2
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... EurekAlert! in 2010 was the discovery of a "golden ... finding put forth the new suggestion that matter on ... patterns as opposed to chaos. Stories on the ... EurekAlert! users in 2010. The most popular topics varied ...
... HealthDay Reporter , TUESDAY, March 22 (HealthDay News) -- ... reduce the risk of developing high blood pressure, a new ... risk of developing hypertension in those who consumed whole grain ... researcher Dr. Jinesh Kochar, of Beth Israel Deaconess Medical Center ...
... March 23 (HealthDay News) -- Reducing the workload of U.S. ... has not had a negative effect on patient safety and ... a new study contends. The findings, which stem from ... and United Kingdom, challenge concerns expressed by medical professionals that ...
... Chase, MD A recent study accepted for publication in The ... (JCEM) found that higher levels of perfluorocarbons (PFCs) in the ... in women between 42 and 64 years old. Women in ... significantly lower concentrations of estrogen when compared to women who ...
... of a young, apparently healthy athlete dying on the court or ... at Fennville High School, who died of cardiac arrest from an ... if enough is being done to identify athletes at risk for ... program to help prevent sudden cardiac death, but there is not ...
... In 1998, a study linking the measles, mumps and ... respected medical journal. For a decade, the study grabbed headlines ... and those with autistic children agonized that they allowed an ... was a fraud. The paper was retracted 12 years later, ...
Cached Medicine News:Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 2Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 3Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 4Health News:Physics story tops EurekAlert!'s 2010 list of most-visited releases 5Health News:Whole Grain Cereal May Help Control Blood Pressure 2Health News:Whole Grain Cereal May Help Control Blood Pressure 3Health News:Exposure to chemicals in environment associated with onset of early menopause 2Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:Research practices must be changed to minimize fraud, deception 2
... is the first and only ... 3 layers of the tear ... that lubricates and protects the ... helps seal in moisture and ...
...
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
ALOCRIL® ophthalmic solution is a prescription eye drop for itchy allergy eyes. ALOCRIL® provides control beyond relief by providing continuous symptom control throughout the allergy season....
Medicine Products: